TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer
American Journal of Cancer Research · 2024 · 14 (5) · 2493-2506
DOI: 10.62347/mqff6404 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2024. Verfasst von Jibran Ahmed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health Bethesda, MD, …. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
TIM-3, an inhibitory checkpoint receptor, may invoke anti-PD-1/anti-PD-L1 immune checkpoint inhibitor (ICI) resistance. The predictive impact of TIM-3 RNA expression in various advanced solid tumors among patients treated with ICIs is yet to be determined, and their prognostic significance also remains unexplored. We investigated TIM-3 transcriptomic expression and clinical outcomes. We examined TIM-3 RNA expression data through the OmniSeq database. TIM-3 transcriptomic patterns were calibrated against a reference population (735 tumors), adjusted to internal housekeeping genes, and calculated as percentiles. Overall, 514 patients (31 cancer types; 489 patients with advanced/metastatic disease and clinical annotation) were assessed. Ninety tumors (17.5% of 514) had high (≥75th percentile RNA rank) TIM-3 expression. Pancreatic cancer had the greatest proportion of TIM-3 high expressors (36% of 55 patients). Still, there was variability within cancer types with, for instance, 12.7% of pancreatic cancers harboring low TIM-3 (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health Bethesda, MD, The United Sates.
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center La Jolla, CA, The United States.
- Dartmouth Cancer Center, Hematology and Medical Oncology Lebanon, NH, The United States.
- OmniSeq Inc. (Labcorp) Buffalo, NY, The United States.
- Department of Surgery, Division of Surgical Oncology, University of California San Diego San Diego, CA, The United States.
- Department of Pharmacology, University of California San Diego San Diego, CA, The United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Ahmed, J., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M. K., Pabla, S., Conroy, J. M., DePietro, P., Sicklick, J. K., Kato, S., & Kurzrock, R. (2024). TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. American Journal of Cancer Research, 14(5), 2493-2506. https://doi.org/10.62347/mqff6404
Vancouver
Ahmed J, Nishizaki D, Miyashita H, Lee S, Nesline MK, Pabla S, et al. TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. American Journal of Cancer Research. 2024;14(5):2493-2506. doi:10.62347/mqff6404
BibTeX
@article{Ahmed2024,
author = {Ahmed, Jibran and Nishizaki, Daisuke and Miyashita, Hirotaka and Lee, Suzanna and Nesline, Mary K and Pabla, Sarabjot and Conroy, Jeffrey M and DePietro, Paul and Sicklick, Jason K and Kato, Shumei and Kurzrock, Razelle},
title = {TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer},
journal = {American Journal of Cancer Research},
year = {2024},
volume = {14},
number = {5},
pages = {2493--2506},
doi = {10.62347/mqff6404}
}
EUVIMED